CCND1 and cancer: Silencing METTL7B leads to downregulation of the cell cycle regulator cyclin D1 (CCND1) and upregulation of cyclin-dependent kinase 4 inhibitor (CDKN4), resulting in G0/G1 phase arrest in cancer cells and a significant reduction in their proliferative capacity both in vitro and in vivo [96].